Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy

Journal of the Neurological Sciences

Volumn 344, Issue 1-2, 2014, Pages 193-197

  Hellmann, M A ^a,b   Lev, N ^a,b   Lotan, I ^a,b   Mosberg Galili, R ^a,b   Inbar, E ^a,b   Luckman, J ^a,b   Fichman Horn, S ^a,b   Yakimov, M ^a,b   Steiner, I ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Fingolimod; Immune suppression; Multiple sclerosis; Side effects; Therapy; Tumefective

Indexed keywords

FINGOLIMOD; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; BRAIN BIOPSY; BRAIN DAMAGE; CASE REPORT; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REBOUND; ANALOGS AND DERIVATIVES; BRAIN INJURY; CHEMICALLY INDUCED; ENCEPHALITIS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BRAIN INJURIES; ENCEPHALITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OCCIPITAL LOBE; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84929048520     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.06.013     Document Type: Article

References (22)

1. D. Pelletier, and D.A. Hafler Fingolimod for multiple sclerosis N Engl J Med 366 2012 339 347
2. L. Daelman, A. Maitrot, A. Maarouf, M.P. Chaunu, C. Papeix, and A. Tourbah Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal Mult Scler 18 2012 1647 1649
3. J.H. Min, B.J. Kim, and K.H. Lee Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder Mult Scler 18 2012 113 115
4. F. Rinaldi, D. Seppi, and M. Calabrese et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings Mult Scler 18 2012 1640 1643
5. D. Ferraro, L. Federzoni, F. Vitetta, A.M. Simone, A. Cossarizza, and P.F. Nichelli et al. Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect? Mult Scler 19 2013 1550
6. D. Centonze, S. Rossi, F. Rinaldi, and P. Gallo Severe relapses under fingolimod treatment prescribed after natalizumab Neurology 79 2012 2004 2005
7. F. Castrop, M.C. Kowarik, H. Albrecht, M. Krause, B. Haslinger, and C. Zimmer et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology 78 2012 928 930
8. A. Ghezzi, M.A. Rocca, D. Baroncini, P. Annovazzi, M. Zaffaroni, and G. Minonzio et al. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients J Neurol 260 2013 327 329
9. J.B. Havia, H.L. Pellkofer, and L. Meini et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment Arch Neurol 69 2012 262 264
10. E. Piscolla, B. Hakiki, L. Pastò, L. Razzolini, E. Portaccio, and M.P. Amato Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient J Neurol 260 2013 1675 1677
11. F. Visser, M.P. Wattjes, P.J. Pouwels, W.H. Linssen, and B.W. van Oosten Tumefactive multiple sclerosis lesions under fingolimod treatment Neurology 79 2012 2000 2003
12. J.A. Cohen, F. Barkhof, and G. Comi et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
13. F. Leypoldt, A. Munchau, and F. Moeller et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report Neurology 72 2009 1022 1024
14. S. Jander, B. Turowski, B.C. Kieseier, and H.P. Hartung Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod Mult Scler 18 2012 1650 1652
15. M.O. Kinney, and G. McDonnell Tumefactive multiple sclerosis lesions under fingolimod treatment Neurology 81 2013 403
16. G. Pilz, A. Harrer, P. Wipfler, K. Oppermann, J. Sellner, and F. Fazekas et al. Neurology 81 2013 1654 1658
17. C.F. Lucchinetti, R.H. Gavrilova, I. Metz, J.E. Parisi, B.W. Scheithauer, and S. Weigand et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis Brain 131 2008 1759 1775
18. K. Hawkins, and M.M. Behrens Homonymous hemianopia in multiple sclerosis with report of bilateral case Br J Ophthalmol 59 1975 334 337
19. D.L. Barber, B.B. Andrade, I. Sereti, and A. Sher Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none Nat Rev Microbiol 10 2012 150 156
20. I. Steiner PML: underdiagnosed in MS patients on natalizumab Lancet Neurol 9 2010 564
21. B. Soliven, V. Miron, and J. Chun The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators Neurology 76 2011 S9 S14
22. P. Friedemann, and D. Bourdette Tumefactive multiple sclerosis and fingolimod. Immunotherapies and unintended consequences Neurology 81 2013 1648 1649